Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 88.23% is 125% above its 3-year average of 39.28%, near the high end of its 3-year range (0.00%–100.00%).
1.96% below its 12-month average of 89.99%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
88.23%
GROSS MARGIN AVG TTM
89.99%
GROSS MARGIN AVG 3Y
42.31%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.96%
CURRENT VS 3Y AVG
+108.55%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.82%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
+116.14%
vs the sector median at left
Market Cap
$844.23M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$840.45M
Gross Margin
44.60%
TTM Avg
46.45%
3Y Avg
50.53%
5Y Avg
59.76%
Market Cap
$859.14M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
Market Cap
$825.69M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$874.76M
Gross Margin
91.39%
TTM Avg
91.47%
3Y Avg
93.85%
5Y Avg
95.64%
Market Cap
$819.99M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
Market Cap
$883.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $847.45M | 88.23% | 89.99% | 42.31% | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $844.23M | 58.31% | 55.25% | 65.77% | 65.77% |
| QuidelOrtho Corporation (QDEL)vs › | $840.45M | 44.60% | 46.45% | 50.53% | 59.76% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $859.14M | 92.94% | 91.25% | 45.63% | 30.42% |
| Jade Biosciences, Inc. (JBIO)vs › | $825.69M | 0.00% | 0.00% | 0.00% | 0.00% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $874.76M | 91.39% | 91.47% | 93.85% | 95.64% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $819.99M | 35.97% | 27.94% | 30.11% | 34.47% |
| Ardelyx, Inc. (ARDX)vs › | $812.21M | 93.96% | 87.19% | 88.05% | 90.06% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $883.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| InMode Ltd. (INMD)vs › | $805.36M | 76.52% | 79.43% | 81.57% | 82.72% |
Gross Margin
88.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 49.97% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
